Edge Wealth Management LLC raised its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 252.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,021 shares of the financial services provider’s stock after buying an additional 36,559 shares during the quarter. iShares Nasdaq Biotechnology ETF comprises 1.4% of Edge Wealth Management LLC’s portfolio, making the stock its 23rd biggest holding. Edge Wealth Management LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $4,920,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Schroder Investment Management Group purchased a new stake in iShares Nasdaq Biotechnology ETF during the 2nd quarter worth approximately $105,000. Benjamin F. Edwards & Company Inc. lifted its position in shares of iShares Nasdaq Biotechnology ETF by 636.4% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 891 shares of the financial services provider’s stock worth $109,000 after purchasing an additional 770 shares in the last quarter. North Star Investment Management Corp. lifted its position in shares of iShares Nasdaq Biotechnology ETF by 21.6% in the fourth quarter. North Star Investment Management Corp. now owns 1,180 shares of the financial services provider’s stock worth $114,000 after purchasing an additional 210 shares in the last quarter. Cypress Capital Management LLC acquired a new position in iShares Nasdaq Biotechnology ETF during the third quarter worth $201,000. Finally, Truvestments Capital LLC acquired a new position in iShares Nasdaq Biotechnology ETF during the third quarter worth $203,000. Institutional investors and hedge funds own 64.33% of the company’s stock.

Shares of NASDAQ:IBB traded up $0.14 on Friday, hitting $109.04. The company had a trading volume of 223,772 shares, compared to its average volume of 2,745,966. iShares Nasdaq Biotechnology ETF has a 1-year low of $89.01 and a 1-year high of $122.97.

COPYRIGHT VIOLATION WARNING: “iShares Nasdaq Biotechnology ETF (IBB) Shares Bought by Edge Wealth Management LLC” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2019/01/11/ishares-nasdaq-biotechnology-etf-ibb-shares-bought-by-edge-wealth-management-llc.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Article: Return on Equity (ROE)

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.